JAKARTA - Coordinating Minister for Human Development and Culture (Menko PMK) Muhadjir Effendy requested that the production process of the Red and White Vaccine can be accelerated. The goal is that the domestically made COVID-19 vaccine product can be immediately used in the implementation of vaccination.

According to a government press release received in Jakarta, Thursday, the development of the Red and White Vaccine is currently being carried out by Airlangga University with PT Biotis, PT Bio Farma with Baylor College of Medicine, University of Indonesia with PT Etana, Bandung Institute of Technology, PRBM Eijkman BRIN and PT Bio Farma, as well as Padjadjaran University with PT Bio Farma and Lipotek.

The Red and White vaccine developed by Universitas Airlangga and PT Biotis is planned to be released in early 2022 and is expected to be ready for mass production in mid-2022.

In a coordination meeting regarding domestic vaccine production in Jakarta, Wednesday, January 12 yesterday, Muhadjir asked the Ministry of Health to make efforts to immediately produce the Red and White Vaccine.

"So that it can be accelerated without reducing the quality, precision, and accuracy of the products," he said as quoted by Antara.

Muhadjir hopes that the fruit of the hard work of the research team that developed the Red and White Vaccine can be immediately used to support efforts to overcome COVID-19 in Indonesia.

"If we can achieve the maximum target, so that we end the end of this outbreak with a domestically made vaccine," he said.

"It is more husnul khatimah in the language of religion, because we are proud to be able to plant the Red and White Flag high because we can solve it with the vaccine we have," he added.

Muhadjir also explained that the development of a COVID-19 vaccine in the country was carried out by the government together with the pharmaceutical industry, research institutions, and universities.

Meanwhile, Minister of Health Budi Gunadi Sadikin stated that the primary Red and White Vaccine could be launched in March 2022 at the latest and the vaccine product is targeted to be used for primary vaccination in children by June 2022 at the latest.

Meanwhile, the use of domestic vaccine products as boosters, according to him, can be postponed until August 2022 by considering the response to providing vaccine products from abroad in primary vaccination and booster vaccination using domestically produced vaccines.


The English, Chinese, Japanese, Arabic, and French versions are automatically generated by the AI. So there may still be inaccuracies in translating, please always see Indonesian as our main language. (system supported by DigitalSiber.id)